Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Subject/Evaluator Blind, Active Control, Phase II/III Clinical Trial to Assess Immunogenicity and Safety of EG-MCV4 Meningococcal (Groups A, C, W-135, and Y) Conjugated Vaccines

NCT07204457 is registered in ClinicalTrials.gov with EyeGene Inc. as lead sponsor.

NCT NCT07204457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07204457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Subject/Evaluator Blind, Active Control, Phase II/III Clinical Trial to Assess Immunogenicity and Safety of EG-MCV4 Meningococcal (Groups A, C, W-135, and Y) Conjugated Vaccines
Lead sponsor
EyeGene Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 15, 2025
Completion date
June 30, 2027
Enrollment
1,123 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal infections